



On July 11, 2022, the Centers for Medicare & Medicaid Services (CMS) published final rule CMS-3355-F. This rule introduces new regulated analytes to CLIA, updates grading criteria for some existing analytes, and implements additional changes that impact PT enrollment and grading.

Prepare your laboratory for the upcoming changes in CLIA proficiency testing (PT) regulations, which will be implemented on January 1, 2025. Refer to the table below, to review the new CMS regulated analytes, their acceptance limits, and corresponding program codes.

Contact us for assistance. contactcenter@cap.org 800-323-4040, Option 1 | +1-847-832-7000, Option 1.

| New CMS Regulated Analytes | | | |
|---|--|---|--|
| Analyte | Program Code(s) | Current Criteria | New CMS Criteria |
| CHEMISTRY | | | |
| BNP | BNP5, PCARM, PCARMX | Target value \pm 3 SD or 10% (greater) | Target value \pm 30% |
| NT pro-BNP | BNP5, PCARM, PCARMX | Target value \pm 3 SD or 10% (greater) | Target value \pm 30% |
| CO ₂ , total | AQ, AQH, AQIS, C1/C3/C3X/C4/CZ/CZ X/CZ2X | Target value \pm 3 SD | Target value \pm 20% |
| LDL Cholesterol, measured | C1/C3/C3X/C4/CZ/CZ X/CZ2X | Target value \pm 30% | Target value \pm 20% |
| Ferritin | C1/C3/C3X/CZ/CZX/C Z2X, K/KK | Target value \pm 3 SD | Target value \pm 20% |
| Gamma glutamyl transferase (GGT) | C1/C3/C3X/CZ/CZX/C Z2X | Target value \pm 3 SD | Target value \pm 15% or 5 U/L(greater) |
| Hemoglobin A1c | GH5, GH5I | Target value \pm 6% | Target value \pm 8%* |
| Phosphorus | C1/C3/C3X/CZ/CZX/C Z2X | Target value \pm 10.7% or 0.3 mg/dL (greater) | Target value \pm 10% or 0.3 mg/dL(greater) |
| Prostate-specific antigen (PSA), total | K/KK | Target value \pm 3 SD or 0.2 ng/mL (greater) | Target value \pm 20% or 0.2 ng/mL (greater) |
| Iron-binding capacity, total (TIBC), measured | C3/C3X/CZ/CZX/CZ2X | Target value \pm 20% | Target value \pm 20% |
| Troponin I | CRT, CRTI, PCARM, PCARMX | Target value \pm 3 SD or 30% (greater) | Target value \pm 30% or 0.9 ng/mL (greater) |
| ENDOCRINOLOGY | | | |
| Cancer antigen (CA) 125 | K/KK | Target value \pm 3 SD | Target value \pm 20% |
| Carcinoembryonic antigen (CEA) | K/KK | Target value \pm 25% or 1.2 ng/mL (greater) | Target value \pm 15% or 1 ng/mL (greater) |
| Estradiol | Y/YY | Target value \pm 3 SD | Target value \pm 30% |
| Folate | K/KK | Target value \pm 3 SD | Target value \pm 30% or 1 ng/mL (greater) |
| Follicle-stimulating hormone (FSH) | Y/YY | Target value \pm 3 SD | Target value \pm 18% or 2 IU/L (greater) |
| Luteinizing hormone (LH) | Y/YY | Target value \pm 3 SD | Target value \pm 20% |
| Parathyroid hormone (PTH) | PTH | Target value \pm 3 SD | Target value \pm 30% |
| Progesterone | Y/YY | Target value \pm 3 SD | Target value \pm 25% |
| Prolactin | Y/YY | Target value \pm 3 SD | Target value \pm 20% |
| Testosterone | Y/YY | Target value \pm 3 SD | Target value \pm 30% or 20 ng/dL (greater) |
| Vitamin B12 | K/KK | Target value \pm 3 SD | Target value \pm 25% or 30 pg/mL (greater) |
| TOXICOLOGY | | | |
| Acetaminophen | CZ/CZX/CZ2X/Z | Target value \pm 3 SD or 10% (greater) | Target value \pm 15% or 3 mcg/mL (greater) |
| Salicylate | CZ/CZX/CZ2X/Z | Target value \pm 3 SD or 10% (greater) | Target value \pm 15% or 2 mcg/mL (greater) |
| Vancomycin | CZ/CZX/CZ2X/Z | Target value \pm 3 SD or 10% (greater) | Target value \pm 15% or 2 mcg/mL (greater) |
| HEMATOLOGY (including Coagulation) | | | |
| INR | CGB, CGL, WP3, WP4, WP6, WP9 | Target value \pm 20% | Target value \pm 15% |
| IMMUNOLOGY | | | |
| CRP, high sensitivity | HSCRP | Target value \pm 30% | Target value \pm 30% or 1 mg/L (greater) |
| Anti-HBs (HBsAb) | VM1 | Reactive (positive) or non-reactive (negative) | Reactive (positive) or non-reactive (negative) |
| Anti-HCV | VM1 | Reactive (positive) or non-reactive (negative) | Reactive (positive) or non-reactive (negative) |

*CAP-accredited laboratories that use accuracy-based proficiency testing for hemoglobin A1c will be required to evaluate results based on acceptable performance criteria of \pm 6% in 2025. Therefore, the CAP will provide two evaluations starting with the GH5-A 2025 mailing to meet CLIA (Target value \pm 8%) and CAP checklist (Target value \pm 6%) requirements.

| Revised Scoring Criteria for Currently Regulated Analytes | | | |
|--|------------------------|-----------------------------|---|
| CHEMISTRY | | | |
| Analyte | | Current CMS Criteria | New CMS Criteria |
| Alanine aminotransferase (ALT/SGPT) | C1/C3/C3X/CZ/CZX/C Z2X | Target value \pm 20% | Target value \pm 15% or 6 U/L (greater) |

| | | | |
|---------------------------------------|--|--|--|
| Albumin | C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 10% | Target value ± 8% |
| Alkaline Phosphatase | C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 30% | Target value ± 20% |
| Amylase | C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 30% | Target value ± 20% |
| Aspartate aminotransferase (AST/SGOT) | C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 20% | Target value ± 15% or 6 U/L (greater) |
| pO2 | AQ, AQH, AQIS | Target value ± 3 SD | Target value ± 15% or 15 mmHg (greater) |
| HDL Cholesterol | C1/C3/C3X/C4/CZ/CZ/X/CZ2X | Target value ± 30% | Target value ± 20% or 6 mg/dL (greater) |
| Creatine Kinase (CK) | C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 30% | Target value ± 20% |
| CK-MB isoenzyme | CRT, CRTI, HCRT, HCRTI | Target value ± 3 SD | Target value ± 25% or 3 ng/mL (greater) |
| Creatinine | AQ, AQH, AQIS, C1/C3/C3X/C4/CZ/CZ/X/CZ2X, WBCR | Target value ± 15% or 0.3 mg/dL (greater) | Target value ± 10% or 0.2 mg/dL (greater) |
| Glucose | AQ, AQH, AQIS, C1/C3/C3X/C4/CZ/CZ/X/CZ2X | Target value ± 10% or 6 mg/dL (greater) | Target value ± 8% or 6 mg/dL (greater) |
| Iron | C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 20% | Target value ± 15% |
| Lactate dehydrogenase (LD) | C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 20% | Target value ± 15% |
| Magnesium | C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 25% | Target value ± 15% |
| Potassium | AQ, AQH, AQIS, C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 0.5 mmol/L | Target value ± 0.3 mmol/L |
| Protein, total | C1/C3/C3X/CZ/CZX/CZ2X | Target value ± 10% | Target value ± 8% |
| Triglycerides | C1/C3/C3X/C4/CZ/CZ/X/CZ2X | Target value ± 25% | Target value ± 15% |
| Uric Acid | C1/C3/C3X/C4/CZ/CZ/X/CZ2X | Target value ± 17% | Target value ± 10% |
| ENDOCRINOLOGY | | | |
| Analyte | | Current CMS Criteria | New CMS Criteria |
| Alpha-fetoprotein (AFP) | K/KK, FP/FPX | Target value ± 3 SD | Target value ± 20% |
| Cortisol | C1/C3/C3X/C4/CZ/CZ/X/CZ2X, K/KK | Target value ± 25% | Target value ± 20% |
| Thyroxine (T4), free | C1/C3/C3X/C4/CZ/CZ/X/CZ2X, K/KK | Target value ± 3 SD | Target value ± 15% or 0.3 ng/dL (greater) |
| hCG serum | C1/C3/C3X/C4/CZ/CZ/X/CZ2X, FP/FPX/FP1T, HCG, IL, K/KK | Target value ± 3 SD | Target value ± 18% or 3 mIU/mL (greater) |
| T3 Uptake and related tests | C1/C3/C3X/C4/CZ/CZ/X/CZ2X, K/KK | Target value ± 3 SD | Target value ± 18% |
| Triiodothyronine (T3) | C1/C3/C3X/C4/CZ/CZ/X/CZ2X, K/KK | Target value ± 3 SD | Target value ± 30% |
| Thyroid-stimulating hormone (TSH) | C1/C3/C3X/C4/CZ/CZ/X/CZ2X, K/KK | Target value ± 3 SD | Target value ± 20% or 0.2 mIU/L (greater) |
| TOXICOLOGY | | | |
| Analyte | | Current CMS Criteria | New CMS Criteria |
| Alcohol | AL1, AL2 | Target value ± 25% | Target value ± 20% |
| Blood Lead | BL | Target value ± 10% or 4 mcg/dL (greater) | Target value ± 10% or 2 mcg/dL (greater) |
| Carbamazepine | CZ/CZX/CZ2X/Z | Target value ± 25% | Target value ± 20% or 1 mcg/mL (greater) |
| Digoxin | CZ/CZX/CZ2X/Z | Target value ± 20% or 0.2 ng/mL (greater) | Target value ± 15% or 0.2 ng/mL (greater) |
| Lithium | C1/C3/C3X/CZ/CZX/CZ2X/Z | Target value ± 20% or 0.3 mmol/L (greater) | Target value ± 15% or 0.3 mmol/L (greater) |
| Phenobarbital | CZ/CZX/CZ2X/Z | Target value ± 20% | Target value ± 15% or 2 mcg/mL (greater) |
| Phenytoin | CZ/CZX/CZ2X/Z | Target value ± 25% | Target value ± 15% or 2 mcg/mL (greater) |
| Theophylline | CZ/CZX/CZ2X/Z | Target value ± 25% | Target value ± 20% |
| Tobramycin | CZ/CZX/CZ2X/Z | Target value ± 25% | Target value ± 20% |
| Valproic Acid | CZ/CZX/CZ2X/Z | Target value ± 25% | Target value ± 20% |
| HEMATOLOGY | | | |
| Analyte | | Current CMS Criteria | New CMS Criteria |
| Red blood cell count | FH1, FH2, FH3, FH4, FH9, FH10, FH13, FH16, FH17, HE | Target value + 6% | Target value ± 4% |
| Hematocrit | AQH, AQIS, FH1, FH2, FH3, FH4, FH9, FH10, FH13, FH16, FH17, HE, SO | Target value + 6% | Target value ± 4% |

| | | | |
|--|--|-----------------------------|---|
| Hemoglobin | AQH, AQIS, FH1, FH2, FH3, FH4, FH9, FH10, FH13, FH16, FH17, HE, SO | Target value + 7% | Target value ± 4% |
| WBC count | FH1, FH2, FH3, FH4, FH9, FH10, FH13, FH16, FH17, HE | Target value + 15% | Target value ± 10% |
| Participants will be required to enroll in proficiency testing for both manual and automated blood cell differentials. | | | |
| IMMUNOLOGY | | | |
| Analyte | | Current CMS Criteria | New CMS Criteria |
| Alpha-1-Antitrypsin | IG/IGX | Target value ± 3 SD | Target value ± 20% |
| Complement C3 | IG/IGX | Target value ± 3 SD | Target value ± 15% |
| Complement C4 | IG/IGX | Target value ± 3 SD | Target value ± 20% or 5 mg/dL (greater) |
| IgA | IG/IGX | Target value ± 3 SD | Target value ± 20% |
| IgE | IG/IGX, K/KK, SE | Target value ± 3 SD | Target value ± 20% |
| IgG | IG/IGX | Target value ± 25% | Target value ± 20% |
| IgM | IG/IGX | Target value ± 3 SD | Target value ± 20% |
| TRANSFUSION MEDICINE | | | |
| Unexpected antibody detection | J, JAT | Passing Score of 80% | Passing Score of 100% |

| Microbiology Specialty | | | |
|--|-----------------------|--|--|
| | Analyte/Method | Program Code(s) | |
| BACTERIOLOGY | | | |
| Antimicrobial Susceptibility Testing changing to 2 challenges per mailing | | D, D2, RMC | |
| | <i>C. difficile</i> | CDF5, D, GIP5 | |
| Bacterial Toxin Detection | Shigatoxin | GIP5 | |
| Gram Stain Morphology | | D, D2, D3, D5, RMC | |
| Detection of the Presence or Absence of Bacteria without Identification | | For the subspecialty of Bacteriology, a reporting option of presence or absence of bacteria without identification will be allowed | |
| MYCOBACTERIOLOGY | | | |
| Mycobacteriology Identification | Molecular | MTR5 | |
| Detection of the Presence or Absence of Mycobacteria without Identification | | For the subspecialty of Mycobacteriology, a reporting option of presence or absence of mycobacteria without identification will be allowed | |
| MYCOLOGY | | | |
| Fungal Identification | Molecular | IDM5, MVP, VS, YBC | |
| Direct Fungal Antigen Detection | | CRYP, F, F1 | |
| Detection of the Presence or Absence of Fungi and Aerobic Actinomycetes without Identification | | For the subspecialty of Mycology, a reporting option of presence or absence of fungi or aerobic actinomycetes without identification will be allowed | |
| PARASITOLOGY | | | |
| Identification of Parasites | Molecular | GIP5, MVP, STIM, TVG5, VS | |
| Direct Parasite Antigen Detection | | P, P3, P4, P5, RML5 | |
| Detection of the Presence or Absence of Parasites without Identification | | For the subspecialty of Parasitology, a reporting option of presence or absence of parasites without identification will be allowed | |
| VIROLOGY | | | |
| No changes | | | |